Detail of "79275-73-3"

Reference

Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women

Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Mueck, Alfred O.; Seeger, Harald (Section of Endocrinology and Menopause, University Women's Hospital, Tuebingen 72 076, Germany). Maturitas, 49(3), 189-203 (English) 2004 Elsevier Ltd.Chemicals with cas numbers 152-62-5 and 79275-73-3 also play role. CODEN: MATUDK. ISSN: 0378-5122. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) Section cross-reference(s): 14 High blood pressure (BP) ranks as the greatest risk factor for cardiovascular disease. The increased cardiovascular risk detd. in recent interventional studies has led the health authorities in some countries to re-ignite the discussion about whether hypertension should be listed as a contraindication for hormone replacement therapy (HRT). We reviewed papers published since 1960 and listed in MEDLINE, EMBASE and Biosis, on studies that monitored the course of BP during HRT. We found that both primarily normotensive and hypertensive postmenopausal women actually run only a very low risk of BP increase during HRT, indeed, BP was often lowered. In one of our own studies 1397 hypertensive women with BP diastolic >95 mmHg received transdermal HRT regimens; BP was lowered by an av. of 7 mmHg systolic and 9 mmHg diastolic. The results of the more recent 24-h ambulatory BP studies are particularly conclusive. At least 19 such studies have been performed, 13 placebo-controlled and 10 cross-over; 5 found no effect on BP and 14 studies demonstrated BP redns. BP was lowered by treatment with transdermal estradiol in 11 of 13 studies and by oral estrogen in 4 of 11 studies. The effects were not consistent with regard to systolic or diastolic BP nor to action on day- and night-time BP. It cannot be ruled out that some women with a particular predisposition exhibit an abnormal reaction to the vasoactive effects of HRT, and there is a paucity of long-term data on risk populations, specifically on the progestogenic effects in patients with pre-existing arteriosclerotic lesions. In conclusion, the risk of developing hypertension during HRT is very low, but hormone therapy should always be appropriately indicated and during therapy BP should be checked regularly. .

Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy

Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Akkad, Andrea A.; Halligan, Aidan W. F.; Abrams, Keith; Al-Azzawi, Farook (Menopause Research Unit, Department of Obstetrics and Gynecology, Leicester University School of Medicine, Leicester, UK). Obstetrics and Gynecology (New York), 89(1), 97-103 (English) 1997 Elsevier. CODEN: OBGNAS. ISSN: 0029-7844. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) The aim of this study was to examine the effects of oral and transdermal estrogen replacement therapy (ERT) on ambulatory 24-h blood pressure (BP) recordings. In a nonrandomized, prospective study, 90 normotensive, oophorectomized women, ages 30-59 yr, underwent ambulatory 24-h BP measurements at study entry and after 3 and 6 mo of either oral or transdermal ERT. In the women receiving transdermal estrogen, we obsd. a change in mean nighttime systolic BP of -4.2 mmHg (95% confidence interval [CI] -7.7, -0.7) after 6 mo' treatment. There was a change in mean daytime diastolic BP after 3 mo (-3.3 mmHg; 95% CI -5.5, -0.9) and 6 mo (-4 mmHg; 95% CI -6.8, -1.2), and in mean nighttime diastolic BP after 3 mo (-3.8 mmHg; 95% CI -6.6, -0.9) and 6 mo (-4.4 mmHg; 95% CI -7.1; -1.7). No significant BP changes were obsd.There are some commonly used reagents with their cas registry numbers 79275-73-3 and 50-28-2 in this article. in the women taking oral estrogen. Although the statistical power to detect a change of 4 mmHg at the 5% significance level was 90% for diastolic BP, it was weaker for systolic BP (63%) in this group. However, in more than one-third of the women receiving either treatment, a statistically significant increase in BP was obsd. Transdermal ERT was assocd. with a redn. in mean ambulatory BP, whereas oral treatment did not alter BP. Although the overall effect of estrogen was to lower BP, individual responses were variable, and BP increased in more than one-third of the women on either treatment. Therefore, long-term monitoring of ambulatory measurements may be required. .